Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Risk-sharing agreements for innovative drugs: a new solution to old problems?

× No keyword cloud information.

13 in total

Review 1. Advances in cancer therapeutics and patient access to new drugs.

Authors: George Dranitsaris; Ilse Truter; Martie S Lubbe; Eitan Amir; William Evans
Journal: Pharmacoeconomics Date: 2011-03 Impact factor: 4.981

2. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.

Authors: Adrian Towse; Louis P Garrison
Journal: Pharmacoeconomics Date: 2010 Impact factor: 4.981

3. Pharmaceutical risk-sharing agreements.

Authors: Afschin Gandjour
Journal: Pharmacoeconomics Date: 2009 Impact factor: 4.981

Review 4. Performance-Based Risk-Sharing Arrangements: An Updated International Review.

Authors: Josh J Carlson; Shuxian Chen; Louis P Garrison
Journal: Pharmacoeconomics Date: 2017-10 Impact factor: 4.981

Review 5. Sustainable Financing of Innovative Therapies: A Review of Approaches.

Authors: Aidan Hollis
Journal: Pharmacoeconomics Date: 2016-10 Impact factor: 4.981

6. Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?

Authors: Fernando Antoñanzas; Roberto Rodríguez-Ibeas; Carmelo A Juárez-Castelló
Journal: Pharmacoeconomics Date: 2018-07 Impact factor: 4.981

Review 7. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Authors: Jakub Adamski; Brian Godman; Gabriella Ofierska-Sujkowska; Bogusława Osińska; Harald Herholz; Kamila Wendykowska; Ott Laius; Saira Jan; Catherine Sermet; Corrine Zara; Marija Kalaba; Roland Gustafsson; Kristina Garuolienè; Alan Haycox; Silvio Garattini; Lars L Gustafsson
Journal: BMC Health Serv Res Date: 2010-06-07 Impact factor: 2.655

8. Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain.

Authors: Jose Martinez-Raga; Francisco Gonzalez-Saiz; Julian Oñate; Itziar Oyagüez; Eliazar Sabater; Miguel A Casado
Journal: Health Econ Rev Date: 2012-03-29

Review 9. Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts.

Authors: Szymon Jarosławski; Mondher Toumi
Journal: BMC Health Serv Res Date: 2011-10-08 Impact factor: 2.655

10. The use of risk sharing tools for post adoption surveillance of a non pharmacological technology in routine practice: results after one year.

Authors: Carlos Campillo-Artero; Francisco M Kovacs
Journal: BMC Health Serv Res Date: 2013-05-20 Impact factor: 2.655